{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:43:15Z","timestamp":1790649795452,"version":"4.1.0"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Elexacaftor\/Tezacaftor\/Ivacaftor (ETI) has demonstrated significant efficacy in enhancing clinical outcomes for patients with cystic fibrosis (CF). Despite this, comprehensive post-marketing assessments of its adverse drug events (ADEs) remain insufficient. This study aims to analyze the ADEs associated with ETI using the U.S. FDA Adverse Event Reporting System (FAERS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a pharmacovigilance analysis utilizing FAERS data from Q4 2019 to Q3 2024. Reports of ADEs related to ETI were extracted, and disproportionality analyses\u2014including Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS)\u2014were employed to evaluate signal strength. Additionally, a time-to-onset (TTO) analysis was performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 28,366 ETI-related ADEs were identified, spanning 27 organ systems. We identified 322 positive signals, with signals consistent with the drug label including headache (702 cases, ROR 2.75), infective pulmonary exacerbation of CF (691 cases, ROR 384.24), rash (538 cases, ROR 2.72), and cough (507 cases, ROR 3.79). Unexpected signals were also noted, such as anxiety (494 cases, ROR 4.16), depression (364 cases, ROR 4.59), insomnia (281 cases ROR 2.83), nephrolithiasis (79 cases, ROR 3.63) and perinatal depression (4 cases, ROR 13.59). The TTO analysis indicated that the median onset of ADEs was 70\u00a0days, with 37.08% occurring within the first month. Subgroup analyses revealed that females exhibited a higher reporting rank for mental disorder and constipation, whereas in males, they were insomnia, abdominal pain, and nasopharyngitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study highlights both recognized and unexpected ADEs associated with ETI, underscoring the necessity for ongoing monitoring, particularly concerning psychiatric conditions. The subgroup analysis suggests a need for personalized treatment strategies to optimize patient care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1531514","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T03:55:32Z","timestamp":1741751732000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Real-world safety profile of elexacaftor\/tezacaftor\/ivacaftor: a disproportionality analysis using the U.S. FDA adverse event reporting system"],"prefix":"10.3389","volume":"16","author":[{"given":"Chengyu","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linmei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyou","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruizhen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingyong","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B2","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2165\/11599410-000000000-00000","article-title":"Impact of obesity on drug metabolism and elimination in adults and children","volume":"51","author":"Brill","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"B5","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","article-title":"Using MedDRA: implications for risk management","volume":"27","author":"Brown","year":"2004","journal-title":"Drug Saf."},{"key":"B6","doi-asserted-by":"publisher","first-page":"S1569","DOI":"10.1016\/j.jcf.2025.01.010","article-title":"Longer term follow-up of abdominal symptoms (CFAbd-Score) after initiation of Elexacaftor\/Tezacaftor\/Ivacaftor in adults with cystic fibrosis","volume":"14","author":"Caley","year":"2025","journal-title":"J. Cyst. Fibros."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1509310","DOI":"10.3389\/fphar.2024.1509310","article-title":"Safety assessment of tolvaptan: real-world adverse event analysis using the FAERS database","volume":"15","author":"Cao","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1124\/dmd.112.046276","article-title":"Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone","volume":"41","author":"Choi","year":"2013","journal-title":"Drug Metabolism Dispos. Biol. Fate Chem."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1329409","DOI":"10.3389\/fphar.2024.1329409","article-title":"From genomic spectrum of NTRK genes to adverse effects of its inhibitors, a comprehensive genome-based and real-world pharmacovigilance analysis","volume":"15","author":"Cui","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1002\/ppul.27125","article-title":"Effectiveness and safety of elexacaftor\/tezacaftor\/ivacaftor treatment in children aged 6-11 years with cystic fibrosis in a real-world setting","volume":"59","author":"Dacc\u00f2","year":"2024","journal-title":"Pediatr. Pulmonol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1111\/j.1365-2125.2011.04087.x","article-title":"When to publish measures of disproportionality derived from spontaneous reporting databases?","volume":"72","author":"De Boer","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.medcli.2023.06.006","article-title":"Cystic fibrosis: epidemiology, clinical manifestations, diagnosis and treatment","volume":"161","author":"Diab C\u00e1ceres","year":"2023","journal-title":"Med. Clin."},{"key":"B13","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B14","doi-asserted-by":"publisher","first-page":"104169","DOI":"10.1016\/j.lpm.2023.104169","article-title":"Cystic fibrosis","volume":"52","author":"Fajac","year":"2023","journal-title":"Presse Medicale Paris. Fr. 1983"},{"key":"B15","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.biocel.2014.02.023","article-title":"Genetics of cystic fibrosis: CFTR mutation classifications toward genotype-based CF therapies","volume":"52","author":"Fanen","year":"2014","journal-title":"Int. J. Biochem. and Cell Biol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.arbres.2021.12.003","article-title":"The impact of COVID-19 in cystic fibrosis","volume":"58","author":"Flume","year":"2022","journal-title":"Arch. Bronconeumologia"},{"key":"B17","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12916-025-03913-6","article-title":"Adverse events in the nervous system associated with blinatumomab: a real-world study","volume":"23","author":"Gao","year":"2025","journal-title":"BMC Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1378\/chest.09-2940","article-title":"Prevalence of symptoms of anxiety and depression in German patients with cystic fibrosis","volume":"138","author":"Goldbeck","year":"2010","journal-title":"Chest"},{"key":"B19","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.chest.2023.10.043","article-title":"Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor: multidimensional assessment of neuropsychological side effects and physical and mental health outcomes in adolescents and adults","volume":"165","author":"Graziano","year":"2024","journal-title":"Chest"},{"key":"B20","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.jad.2024.07.103","article-title":"Comprehensive analysis of adverse events associated with pimavanserin using the FAERS database","volume":"362","author":"Gu","year":"2024","journal-title":"J. Affect. Disord."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1295261","DOI":"10.3389\/fendo.2023.1295261","article-title":"The role of the hypothalamic-pituitary-adrenal axis in depression across the female reproductive lifecycle: current knowledge and future directions","volume":"14","author":"Hantsoo","year":"2023","journal-title":"Front. Endocrinol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1007\/s40265-019-01233-7","article-title":"Elexacaftor\/ivacaftor\/tezacaftor: first approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"key":"B23","doi-asserted-by":"publisher","first-page":"123364","DOI":"10.1016\/j.jns.2024.123364","article-title":"The real-world safety assessment of Siponimod: a systematic analysis based on the FAERS database","volume":"468","author":"Jiang","year":"2025","journal-title":"J. Neurol. Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","article-title":"CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine","volume":"10","author":"Lopes-Pacheco","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1167407","DOI":"10.3389\/fphar.2023.1167407","article-title":"Dynamics of abdominal symptoms during the start of a new therapy with elexacaftor\/tezacaftor\/ivacaftor using the novel CFAbd-day2day questionnaire","volume":"14","author":"Mainz","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1164\/rccm.202202-0392OC","article-title":"Efficacy and Safety of Elexacaftor\/Tezacaftor\/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study","volume":"206","author":"Mall","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","article-title":"Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications","volume":"57","author":"Mangoni","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/ppul.10230","article-title":"Risk factors for initial acquisition of Pseudomonas aeruginosa in children with cystic fibrosis identified by newborn screening","volume":"35","author":"Maselli","year":"2003","journal-title":"Pediatr. Pulmonol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1097\/MCP.0b013e328365af49","article-title":"Gender and survival in cystic fibrosis","volume":"19","author":"Mcintyre","year":"2013","journal-title":"Curr. Opin. Pulm. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database","volume":"72","author":"Montastruc","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1164\/rccm.200508-1211ST","article-title":"American thoracic society\/European respiratory society statement on pulmonary rehabilitation","volume":"173","author":"Nici","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1164\/rccm.202308-1525OC","article-title":"Elexacaftor\/tezacaftor\/ivacaftor treatment and depression-related events","volume":"209","author":"Ramsey","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1001\/jama.295.1.33-b","article-title":"Clinical practice guidelines for older patients with comorbid diseases","volume":"295","author":"Roland","year":"2006","journal-title":"Jama"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/cphy.c130018","article-title":"Hormonal regulation of hepatic drug biotransformation and transport systems","volume":"3","author":"Ruiz","year":"2013","journal-title":"Compr. Physiol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jcf.2020.07.014","article-title":"Biliary disease and cholecystectomy after initiation of elexacaftor\/ivacaftor\/tezacaftor in adults with cystic fibrosis","volume":"20","author":"Safirstein","year":"2021","journal-title":"J. Cyst. Fibros. Official J. Eur. Cyst. Fibros. Soc."},{"key":"B37","doi-asserted-by":"publisher","first-page":"00127","DOI":"10.1183\/23120541.00127-2017","article-title":"The potentially beneficial central nervous system activity profile of ivacaftor and its metabolites","volume":"4","author":"Schneider","year":"2018","journal-title":"ERJ Open Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.jpainsymman.2008.08.009","article-title":"Pain in children and adults with cystic fibrosis: a comparative study","volume":"38","author":"Sermet-Gaudelus","year":"2009","journal-title":"J. Pain Symptom Manag."},{"key":"B39","doi-asserted-by":"publisher","first-page":"996179","DOI":"10.3389\/fpubh.2022.996179","article-title":"Gastrointestinal adverse events associated with semaglutide: a pharmacovigilance study based on FDA adverse event reporting system","volume":"10","author":"Shu","year":"2022","journal-title":"Front. Public Health"},{"key":"B40","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.chest.2022.08.2240","article-title":"Sex and gender in lung diseases and sleep disorders: a state-of-the-art review: Part 2","volume":"163","author":"Sodhi","year":"2023","journal-title":"Chest"},{"key":"B41","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s41999-021-00587-0","article-title":"Sex-related pharmacokinetic differences with aging","volume":"13","author":"Stader","year":"2022","journal-title":"Eur. Geriatr. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/ppul.22967","article-title":"The cystic fibrosis gender gap: potential roles of estrogen","volume":"49","author":"Sweezey","year":"2014","journal-title":"Pediatr. Pulmonol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Saf."},{"key":"B44","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.jcf.2021.03.006","article-title":"Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation","volume":"20","author":"Taylor-Cousar","year":"2021","journal-title":"J. Cyst. Fibros. Official J. Eur. Cyst. Fibros. Soc."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1002\/ppul.25535","article-title":"Healthcare resource utilization and costs among children with cystic fibrosis in the United States","volume":"56","author":"Thorat","year":"2021","journal-title":"Pediatr. Pulmonol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/pds.4613","article-title":"Benefits of combining change-point analysis with disproportionality analysis in pharmacovigilance signal detection","volume":"28","author":"Trinh","year":"2019","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B47","doi-asserted-by":"publisher","first-page":"4809","DOI":"10.1038\/s41467-020-18396-7","article-title":"Transcriptomic profiling of human cardiac cells predicts protein kinase inhibitor-associated cardiotoxicity","volume":"11","author":"Van Hasselt","year":"2020","journal-title":"Nat. Commun."},{"key":"B48","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"Van Puijenbroek","year":"","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B49","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"Van Puijenbroek","year":"","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1001\/jama.297.11.1233","article-title":"Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review","volume":"297","author":"Van Spall","year":"2007","journal-title":"Jama"},{"key":"B51","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1164\/rccm.202301-0021OC","article-title":"Long-Term Safety and Efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor in Children Aged \u2a7e6 Years with Cystic Fibrosis and at Least One F508del Allele: A Phase 3, Open-Label Clinical Trial","volume":"208","author":"Wainwright","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"995522","DOI":"10.3389\/fphar.2022.995522","article-title":"Data mining and safety analysis of BTK inhibitors: a pharmacovigilance investigation based on the FAERS database","volume":"13","author":"Wan","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1016\/j.ekir.2024.07.006","article-title":"Exploring novel adverse events of nefecon","volume":"9","author":"Wang","year":"2024","journal-title":"Kidney Int. Rep."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2024.2387315","article-title":"Post-marketing safety surveillance of fostamatinib: an observational, pharmacovigilance study leveraging FAERS database","author":"Wei","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"B55","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jad.2017.05.003","article-title":"A systematic review and meta-regression of the prevalence and incidence of perinatal depression","volume":"219","author":"Woody","year":"2017","journal-title":"J. Affect. Disord."},{"key":"B56","doi-asserted-by":"publisher","first-page":"550","DOI":"10.4187\/respcare.01328","article-title":"Relationship between anxiety, depression, and quality of life in adult patients with cystic fibrosis","volume":"57","author":"Yohannes","year":"","journal-title":"Respir. Care"},{"key":"B57","doi-asserted-by":"publisher","first-page":"550","DOI":"10.4187\/respcare.01328","article-title":"Relationship between anxiety, depression, and quality of life in adult patients with cystic fibrosis","volume":"57","author":"Yohannes","year":"","journal-title":"Respir. Care"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A Phase 3 Open-Label Study of Elexacaftor\/Tezacaftor\/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"17534666221144211","DOI":"10.1177\/17534666221144211","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on depression and anxiety in cystic fibrosis","volume":"16","author":"Zhang","year":"2022","journal-title":"Ther. Adv. Respir. Dis."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.3390\/ph17081028","article-title":"Adverse event profiles of adalimumab in children: a disproportionality analysis","volume":"17","author":"Zhang","year":"","journal-title":"Pharm. Basel, Switz."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2024.2393268","article-title":"Adverse events associated with Atogepant: a FAERS-based pharmacovigilance analysis","author":"Zhang","year":"","journal-title":"Expert Opin. Drug Saf."},{"key":"B62","doi-asserted-by":"publisher","first-page":"e33306","DOI":"10.1016\/j.heliyon.2024.e33306","article-title":"Safety assessment of dapagliflozin: real-world adverse event analysis based on the FAERS database from 2012 to 2023","volume":"10","author":"Zhou","year":"2024","journal-title":"Heliyon"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1338902","DOI":"10.3389\/fphar.2024.1338902","article-title":"Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database","volume":"15","author":"Zou","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1055\/s-0029-1222608","article-title":"Platelet function and response to aspirin: gender-specific features and implications for female thrombotic risk and management","volume":"35","author":"Zuern","year":"2009","journal-title":"Semin. Thromb. Hemost."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1531514\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T03:55:35Z","timestamp":1741751735000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1531514\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":64,"alternative-id":["10.3389\/fphar.2025.1531514"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1531514","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,12]]},"article-number":"1531514"}}